Emphysema is a serious lung disease afflicting more than 30 million people worldwide. Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease.
The Pulmonx solution, comprised of the Chartis Pulmonary Assessment System and the Zephyr® Endobronchial Valve, offers a minimally invasive treatment for patients with severe emphysema. The technology identifies appropriate candidates for the therapy and provides a treatment option to significantly improve the lives of patients.
A decade of clinical success with over 10,000 patients treated.
Over 110 publications documenting the safety, efficacy and long-term survival benefits for patients treated with the Zephyr valve.
The Zephyr valve features the broadest clinical experience of any minimally invasive emphysema treatment.